enVVeno Medical Corporation
enVVeno Medical Corporation (NVNOW) Stock Overview
Explore enVVeno Medical Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
74M
P/E Ratio
-3.83
EPS (TTM)
$-1.90
ROE
-0.51%
NVNOW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of enVVeno Medical Corporation (NVNOW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.01.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.83 and a market capitalization of 74M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Robert A. Berman
30
70 Doppler, Irvine, CA
2018